Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
(ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation October 20, 2026 8:00 AM EDT Gary Glick - Founder, President, CEO & DirectorAnthony William Opipari Tyler Van Buren - TD Cowen, Research DivisionEric Schmidt - Cantor Fitzgerald & Co., Research DivisionLut Ming Cheng - JPMorgan Chase & Co, Research DivisionDavid Nierengarten - Wedbush Securities Inc., Research DivisionJeffrey Jones - Oppenheimer & Co.
Inc., Research DivisionAlice NettletonThomas Deal - Raymond James & Associates, Inc., Research Division Good day, and welcome to the Odyssey Therapeutics UEG Week 2026 Investor webcast.
[Operator Instructions] Please note, this call is being recorded.
I'll pass it off to Gary Glick, Founder and CEO of Odyssey Therapeutics.
Gary GlickFounder, President, CEO & Director Good afternoon, everyone, and thank you for joining us.
Earlier today, Bruce Sands presented an update from our Phase IIa monotherapy trial of OD-001 in ulcerative colitis here at UEG Week in Barcelona.
His talk was only 10 minutes long, and so we wanted to give you the rest.
The complete induction data set, biomarkers of colonic and systemic inflammation and mucosal transcriptomics from patient biopsies with enough time to walk through each piece of data and then take your questions.
Just before we begin, a reminder that today's presentation contains forward-looking statements, including statements about the clinical development, efficacy, safety and therapeutic potential of 001 and some of our other product candidates, our regulatory plans and the timing of future milestones.
The actual results may differ materially, so please review the risk factors in our SEC filings.
We'll also show data from other companies' trials.
There have been no head-to-head studies and the data we present today are from an ongoing study, and the trial remains subject to change.
| Product | Price | Change |
|---|---|---|
| Brent Crude | $102.14/bbl | +0.34% |
| WTI Crude | $96.90/bbl | +0.21% |
| EN590 Diesel | $846/MT | +0.18% |
| Jet Fuel A-1 | $1090/MT | +0.55% |
| Mazut M100 | $450/MT | -0.15% |
| Bitumen 60/70 | $470/MT | +0.08% |
| Sulphur Gran 99.5% | $470/MT | -0.44% |
| Urea 46% Gran | $650/MT | +1.12% |
| NPK 16-16-16 | $460/MT | -0.28% |
| Nat Gas TTF | $15.42/MMBtu | +0.92% |
Comments
Post a Comment